Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

BACKGROUND: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in combinatio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Villalobos, Victor M., Mo, Gary, Agulnik, Mark, Pollack, Seth M., Rushing, Daniel A., Singh, Arun, Van Tine, Brian A., McNaughton, Rhian, Decker, Rodney L., Zhang, Wei, Shahir, Ashwin, Cronier, Damien M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997100/
https://ncbi.nlm.nih.gov/pubmed/31821732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2728
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia